Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTCQX: LXRP) on Wednesday announced that, through its
subsidiary Lexaria CanPharm ULC, it has entered a definitive 5-year agreement
to provide Lexaria’s patented DehydraTECH(TM) technology to a private
California-based cannabis company. Under the agreement the cannabis company
will utilize the technology in certain cannabis-based beverages to be produced
and sold in the states of California and Nevada. DehydraTECH-enabled beverages
are protected under Lexaria’s many existing US-granted patents and may include
any combination of ready-to-drink beverages such as non-alcoholic beers, wines
and spirits; cold or hot coffee or teas, sports drinks and much more. In
addition, Lexaria this morning announced the addition of Dr. Dwayne Godwin, Dr.
Terry D. Blumenthal, Dr. Matthew Fraser and Dr. Carla Lema Tome to its
Scientific Advisory Board. Each of the new appointees will contribute support,
advice and recommendations related to the company’s scientific research and
product development. “Lexaria Bioscience Corp. is very pleased to welcome these
accomplished experts to our Advisory Board, who can provide critical scientific
guidance to Lexaria’s ongoing and future R&D programs,” Lexaria CEO Chris
Bunka said in the news release. “Lexaria is building towards becoming one of
the world’s leaders in drug delivery technology and our most recent Advisors
can assist in achieving that goal.”
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
